Important factors for achieving survival of five years or more in non‑small cell lung cancer patients with distant metastasis

Hirashima,Tomonori; Suzuki,Hidekazu; Okamoto,Norio; Morishita,Naoko; Yamadori,Tadahiro; Tamiya,Motohiro; Shiroyama,Takayuki; Kurata,Kanako; Kawase,Ichiro

doi:10.3892/ol.2014.2107

July-2014 Volume 8 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2014 Volume 8 Issue 1

Full Size Image

Article

Important factors for achieving survival of five years or more in non‑small cell lung cancer patients with distant metastasis

Authors:
- Tomonori Hirashima
- Hidekazu Suzuki
- Norio Okamoto
- Naoko Morishita
- Tadahiro Yamadori
- Motohiro Tamiya
- Takayuki Shiroyama
- Kanako Kurata
- Ichiro Kawase
View Affiliations / Copyright

Affiliations: Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino‑shi, Osaka 583‑8588, Japan
Pages: 327-334
|
Published online on: April 30, 2014

https://doi.org/10.3892/ol.2014.2107
Expand metrics +

Abstract

In order to examine which factors were important for achieving a ≥5 year survival time in non‑small cell lung cancer (NSCLC) patients with distant metastasis, 268 NSCLC patients who received first‑line chemotherapy between January 2004 and December 2007 were retrospectively examined. The median survival time of the patients was 14 months, with 22 surviving for ≥5 years, 48 for ≥2 years, but <5 years, and 198 surviving <2 years. Multivariate analysis determined that never having smoked, a good performance status, relapse following thoracic surgery and intra‑thoracic metastasis were significantly favorable prognostic factors, while abdominal metastasis was a significantly poor prognostic factor. The ≥5 years and ≥2‑5 years groups had significantly more favorable prognostic factors than the <2 years group. The never‑smoked status was a particularly important factor for ≥5 years of survival. The ≥5 years and ≥2‑5 years groups achieved a significantly more favorable response to first‑line chemotherapy, and a greater number of regimens, total months of epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitor (TKI) treatment and cytotoxic agent treatment cycles compared with the <2 years group. In total, ~50% of the patients received palliative radiotherapy. In the ≥5 years group, patients with EGFR drug‑sensitive mutations achieved ≥5 years of survival mainly by EGFR‑TKI therapy, while those without EGFR mutations achieved ≥5 years of survival by continuing effective cytotoxic agents. Achievement of >5 years of survival was found to correlate with the presence of favorable prognostic factors, response to first‑line chemotherapy, provision of appropriate EGFR‑TKI therapy according to genetic testing results, continuing effective cytotoxic regimens and the use of radiotherapy as local therapy.

View Figures

View References

1	Mitsudomi T, Morita S, Yatabe Y, et al; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010.
2	Maemondo M, Inoue A, Kobayashi K, et al; North-East Japan Study Group, West Japan Thoracic Oncology Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010.
3	Mitsudomi T, Morita S, Yatabe Y, et al: West Japan Thoracic Oncology Group: Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol. 30(Suppl): 75212012.
4	Inoue A, Kobayashi K, Maemondo M, et al; North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 24:54–59. 2013.
5	Okamoto T, Maruyama R, Shoji F, et al: Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer. 47:85–91. 2005.
6	Satoh H, Ishikawa H, Ohara G, et al: Long-term survivors after chemotherapy in advanced non-small cell lung cancer. Anticancer Res. 27:4457–4460. 2007.
7	Dujon C, Azarian R and Petitpretz P: Long-term survivors of advanced non-small-cell lung cancer: characterisation and prognostic factors in a retrospective study. Rev Mal Respir. 26:952–960. 2009.(In French).
8	Giroux Leprieur E, Lavole A, Ruppert AM, et al: Factors associated with long-term survival of patients with advanced non-small cell lung cancer. Respirology. 17:134–142. 2012.
9	Van Damme V, Govaerts E, Nackaerts K, et al: Clinical factors predictive of long-term survival in advanced non-small cell lung cancer. Lung Cancer. 79:73–76. 2013.
10	Hirashima T, Suzuki H, Kobayashi M, et al: Long-term chemotherapy may prolong survival in advanced non-small-cell lung cancer among responders to first-line chemotherapy. Med Oncol. 29:1629–1637. 2012.
11	Kaira K, Takahashi T, Murakami H, et al: Long-term survivors of more than 5 years in advanced non-small cell lung cancer. Lung Cancer. 67:120–123. 2010.
12	Goldstraw P, Crowley J, Chansky K, et al; International Association for the Study of Lung Cancer International Staging Committe; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007.
13	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidlines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
14	Tamura K, Okamoto I, Kashii T, et al; West Japan Thoracic Oncology Group. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer. 98:907–914. 2008.
15	R Development Core Team. The R Project for Statistical Computing. 2010, http://www.r-project.org. Accessed January 4, 2013
16	Yamazaki K, Sugio K, Yamanaka T, et al: Prognostic factors in non-small cell lung cancer patients with postoperative recurrence following third-generation chemotherapy. Anticancer Res. 30:1311–1315. 2010.
17	Hotta K, Kiura K, Fujiwara Y, et al: Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. PLoS One. 6:e266462011.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Important factors for achieving survival of five years or more in non‑small cell lung cancer patients with distant metastasis

This article is mentioned in:

Abstract

Figure 1

Related Articles